Pharmacoeconomics of hepatic encephalopathy

Pharmacotherapy

Volumn 30, Issue 5 PART 2, 2010, Pages

  Neff, Guy ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cirrhosis; Disease economics; Hepatic encephalopathy; Pharmacoeconomics

Indexed keywords

LACTITOL; LACTULOSE; NEOMYCIN; PLACEBO; RIFAXIMIN;

BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLAPPING TREMOR; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INCIDENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NURSING HOME; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; END STAGE LIVER DISEASE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMANS; LACTULOSE; RIFAMYCINS;

EID: 77951728554     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.pt2.28S     Document Type: Review

References (13)

1. Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2008;2:785-790
2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):3-9.
3. Lewis M, Howdle PD. The neurology of liver failure. QJM 2003;96:623-633
4. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-895
5. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States. Hepatology 2007;45:833-834
6. American Gastroenterological Association. The burden of gastrointestinal diseases, 2001. Available from www.gastro.org/clinicalRes/burdenReport.html. Accessed December 3, 2009.
7. Davis GL, Albright JE, Cook S, et al. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998;28(suppl 4 pt 2):390A.
8. Agency for Healthcare Research and Quality. HCUPnet, healthcare cost and utilization project. Available from www.hcupnet.ahrq.gov. Accessed May 14, 2009.
9. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555
10. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;51:737-741
11. Huang E, Esrailian E, Speigel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007;26:1147-1161 (Pubitemid 47480963)
12. Mantry PS, Munsaf S. Analysis of the effect of rifaximin plus lactulose on hospitalizations in patients with end-stage liver disease. Poster presented at the 59th annual meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, October 31-November 4, 2008.
13. Neff G, Leevy C, Frederick T, et al. Rifaximin reduces the risk of hospitalizations in patients with previous episodes of hepatic encephalopathy: results from a phase 3 placebo-controlled trial. Presented at digestive disease week, Chicago, IL, May 31, 2009.